Weight Loss at First Month and Development of Tolerance as Possible Predictors of 30 mg Phentermine Efficacy at 6 Months
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
The efficacy of anti-obesity drugs usually does not consider the high degree of interindividual variability in responses to the drug which could affect the decision to withdraw the drug early due to ineffectiveness or to continue therapy according to specific expectations of success. The aim of this study was to analyze body weight loss in kilograms during the first month (1 mo-BWLkg) of treatment with 30 mg phentermine and development of tolerance to phentermine, on its 6-month efficacy. One hundred sixty-six subjects with obesity were individually or jointly analyzed in the study. Subjects with 1 mo-BWLkg of <1 kg, 1–3 kg, 3–5 kg, and ≥5 kg reached 6-month mean percentage body weight reductions (BWR%) of approximately 3%, 5%, 10%, and 15%, respectively. Development of late tolerance (4–6 months) to phentermine had a lower impact than early tolerance (2–3 months). Subjects with 1 mo-BWLkg < 3 kg who developed early tolerance did not achieve relevant BWR% (≥5%) at month 6, while the rest of the subgroups achieved increasing and progressive BWR%, according to their 1 mo-BWLkg range and time of onset of tolerance. The 1 mo-BWLkg and development of tolerance to phentermine could be useful to predict the expected 6-month efficacy trends in obese patients treated with 30 mg phentermine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“5-15% total weight loss at 6 months 29 -32 (uncontrolled studies)”
From Effectiveness and safety of drugs for obesity (2024) · cites this paper as [30]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obesity : Preventing and managing the global epidemic
Akram, D. S., Astrup, A. V., Atinmo, T., Boissin, J.-L., Bray, G. A., Carroll, K. N., Chitson, P., Chen, C., Dietz, W. H., Hill, J. O., et al. (2000) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 12,945
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
The Epidemiology of Obesity: A Big Picture
Hruby, A., & Hu, F. B. (2015) · PharmacoEconomics · doi:10.1007/s40273-014-0243-x · Cited by 2,916 · cited 1×
“Obesity is a complex, multifactorial, and highly prevalent disease that should be treated accordingly [1].”
BackgroundJensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
Rothman, R. B., Baumann, M. H., Dersch, C. M., Romero, D. V., Rice, K. C., Carroll, F. I., & Partilla, J. S. (2000) · Synapse · doi:10.1002/1098-2396(20010101)39:1<16::aid-syn3>3.0.co;2-# · Cited by 948
Rothman, R. B., Baumann, M. H., Dersch, C. M., Romero, D. V., Rice, K. C., Carroll, F. I., & Partilla, J. S. (2001) · Synapse · doi:10.1002/1098-2396(20010101)39:1<32::aid-syn5>3.0.co;2-3 · Cited by 938
The science of obesity management: an endocrine society scientific statement
Bray, G. A., Heisel, W. E., Afshin, A., Jensen, M. D., Dietz, W. H., Long, M., Kushner, R. F., Daniels, S. R., Wadden, T. A., Tsai, A. G., et al. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00253 · Cited by 812
Obesity: Risk factors, complications, and strategies for sustainable long‐term weight management
Fruh, S. M. (2017) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12510 · Cited by 709 · cited 1×
“The decision to initiate drug therapy for obesity could be guided by the intention to improve chronic diseases or reduce the risk of developing comorbidities such as diabetes mellitus, hypertension, hyperlipidemia, among others, which may be associated with the magnitude of percentage body weight loss [6].”
BackgroundBehavioral treatment of obesity
Butryn, M. L., Webb, V., & Wadden, T. A. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.08.006 · Cited by 636 · cited 1×
“Therefore, drug therapy is frequently used to treat this disease [2,3].”
Background(1989) · PubMed · Cited by 419
Treatment Modalities of Obesity
Hainer, V., Toplak, H., & Mitrakou, A. (2008) · Diabetes Care · doi:10.2337/dc08-s265 · Cited by 231
Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review
Tak, Y. J., & Lee, S. Y. (2021) · The World Journal of Men's Health · doi:10.5534/wjmh.200010 · Cited by 184 · cited 1×
“High interindividual variability is a frequent phenomenon, not only in pharmacotherapy studies, but also in studies of lifestyle change interventions to lose weight [4,18].”
BackgroundSibutramine--a review of clinical efficacy.
Lean, M. E. J. (1997) · PubMed · Cited by 157
Saxon, D. R., Iwamoto, S. J., Mettenbrink, C. J., McCormick, E., Arterburn, D., Daley, M. F., Oshiro, C. E., Koebnick, C., Horberg, M., Young, D. R., et al. (2019) · Obesity · doi:10.1002/oby.22581 · Cited by 152
Factors affecting weight loss variability in obesity
Dent, R., McPherson, R., & Harper, M.-E. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154388 · Cited by 131 · cited 2×
“Nonetheless, high interindividual variability limits the usefulness of these parameters [4].”
BackgroundKang, J. G., Park, C. ‐., Kang, J. H., Park, Y. ‐., & Park, S. W. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01242.x · Cited by 120 · cited 1×
“1 kg weight loss after treatment with 30 mg phentermine for 12 weeks [16].”
MethodUpdates on obesity pharmacotherapy
Velazquez, A., & Apovian, C. M. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13542 · Cited by 115 · cited 2×
“In addition, preoperative weight loss is recommended before bariatric surgery and other procedures like orthopedic hip or knee replacement, for which certain levels of body weight reduction in a specific period of time are required [7].”
BackgroundLewis, K. H., Fischer, H., Ard, J., Barton, L., Bessesen, D. H., Daley, M. F., Desai, J., Fitzpatrick, S. L., Horberg, M., Koebnick, C., et al. (2019) · Obesity · doi:10.1002/oby.22430 · Cited by 110 · cited 1×
“The adverse event profile shown by 30 mg phentermine in this work was similar to those reported in other studies with high phentermine doses [19,20].”
ResultTreatment of Gambling Disorders
Yip, S. W., & Potenza, M. N. (2014) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-014-0014-5 · Cited by 103
Hendricks, E. J., Greenway, F. L., Westman, E. C., & Gupta, A. K. (2011) · Obesity · doi:10.1038/oby.2011.94 · Cited by 97 · cited 1×
“The adverse event profile shown by 30 mg phentermine in this work was similar to those reported in other studies with high phentermine doses [19,20].”
ResultNew Medications for Treatment of Obesity: Metabolic and Cardiovascular Effects
Pucci, A. B. F., & Finer, N. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.11.010 · Cited by 86
2014 EASO Position Statement on the Use of Anti-Obesity Drugs
Toplak, H., Woodward, E., Yumuk, V., Oppert, J.-M., Halford, J. C. G., & Frühbeck, G. (2015) · Obesity Facts · doi:10.1159/000430801 · Cited by 83
Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review
Arbaizar, B., Gómez‐Acebo, I., & Llorca, J. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2008.02.002 · Cited by 69 · cited 1×
“Although the efficacy of various anti-obesity drugs has been related to specific predictors such as the phentermine/topiramate, for patients who report eating disorders [8], naltrexone/bupropion, for patients who struggle with addiction [9,10], or even a cutoff of 1.”
BackgroundPharmacotherapy for Patients with Obesity
Gadde, K. M., Apolzan, J. W., & Berthoud, H.-R. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.272815 · Cited by 57 · cited 2×
“Although the efficacy of various anti-obesity drugs has been related to specific predictors such as the phentermine/topiramate, for patients who report eating disorders [8], naltrexone/bupropion, for patients who struggle with addiction [9,10], or even a cutoff of 1.”
BackgroundThe development of tolerance to drugs that suppress food intake
Fernstrom, J. D., & Choi, S. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.001 · Cited by 50 · cited 1×
“Despite this, we also observed an acceptable level of phentermine efficacy in patients who developed late tolerance [22,23].”
BackgroundObesity: Guidelines, Best Practices, New Research
Apovian, C. M., & Istfan, N. W. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.014 · Cited by 19 · cited 1×
“The release of this neurotransmitter leads to appetite suppression and increased resting energy expenditure [11,13,14].”
BackgroundMaccora, C., Ciuoli, C., Goracci, A., Benenati, N., Formichi, C., Pilli, T., Verdino, V., Mnutr, O. N., Bufano, A., Tirone, A., et al. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0169 · Cited by 19 · cited 1×
“In this sense, the search for predictors of antiobesity efficacy has included the glucagon-like peptide-1 receptor (GLP-1) agonist liraglutide, for which a weight loss ≥ 4 kg after the first month of treatment has a good predictive value for achieving the ≥5% BWL efficacy endpoint [12].”
BackgroundPostmarketing Surveillance Study of the Efficacy and Safety of Phentermine in Patients with Obesity
Kim, H. O., Lee, J. A., Suh, H. W., Kim, Y. S., Kim, B. S., Ahn, E. S., Roh, Y. J., Jung, S. G., Kim, J. M., Kang, M. K., et al. (2013) · Korean Journal of Family Medicine · doi:10.4082/kjfm.2013.34.5.298 · Cited by 17
Initial weight loss as a predictor of response to obesity drugs
Dhurandhar, N., Blank, R. C., Schumacher, D., & Atkinson, R. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0801111 · Cited by 16 · cited 4×
“Although there are no reports of data on this regard for phentermine, it is generally accepted that greater effects of anti-obesity drugs can be achieved in subjects with class 3 obesity [11,24].”
BackgroundInfluentialThree- and six-month efficacy and safety of phentermine in a Mexican obese population
Márquez-Cruz, M., Kammar-García, A., Huerta-Cruz, J. C., Carrasco-Portugal, M. D. C., Barranco-Garduño, L. M., Rodríguez-Silverio, J., González, H. I. R., & Reyes-García, J. G. (2021) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp203943 · Cited by 13
Self-citationdel Valle‐Laisequilla, C. F., Trejo-Jasso, C., Huerta‐Cruz, J. C., Barranco‐Garduño, L. M., Rodríguez‐Silverio, J., Rocha-González, H. I., & Reyes‐García, G. (2018) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp203292 · Cited by 7 · cited 1×
“Although there are no reports of data on this regard for phentermine, it is generally accepted that greater effects of anti-obesity drugs can be achieved in subjects with class 3 obesity [11,24].”
BackgroundSelf-citation
Cited by
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
Añazco, D., & Acosta, A. J. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01599-z · Cited by 43
Mexican Clinical Practice Guidelines for Adult Overweight and Obesity Management
Chávez‐Manzanera, E., Vera-Zertuche, J. M., Kaufer‐Horwitz, M., Vázquez‐Velázquez, V., Flores-Lázaro, J. R., Mireles-Zavala, L., Calzada‐León, R., Garnica-Cuéllar, J. C., Sánchez-Muñoz, V., Ramírez-Butanda, E., et al. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00585-w · Cited by 42
“An observational study of 166 participants found that, among patients receiving phentermine for 6 months, 92.9% of adverse events were mainly mild [107].”
BackgroundInfluentialPhentermine in the Modern Era of Obesity Pharmacotherapy: Does It Still Have a Role in Treatment?
Lewis, K. H., Gudzune, K. A., & Ard, J. D. (2024) · Current Obesity Reports · doi:10.1007/s13679-023-00546-9 · Cited by 25
“In observational studies examining longer-term outcomes of phentermine treatment in real-world settings, mean weight loss has been estimated as high as 11.2% at 6 months [30] or as low as 7.2% at 24 months [22].”
InfluentialFitzgerald, I., Crowley, E. K., Dhubhlaing, C. N., O'Dwyer, S., & Sahm, L. J. (2024) · BJPsych Open · doi:10.1192/bjo.2024.725 · Cited by 18
“As in general weight management, 35 heterogeneity in the responsiveness of AIWG to any intervention was reported by participants.”
Metadata
- Authors
- Rocha-González, H. I., De la Cruz-Álvarez, L. E., Kammar-García, A., Canizales-Quinteros, S., Huerta-Cruz, J. C., Barranco-Garduño, L. M., & Reyes-García, J. G.
- Affiliations
- Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, Col. Casco de Santo Tomas, Miguel Hidalgo, Mexico City 11340, Mexico
- Facultad de Química, Universidad Nacional Autónoma de México, Circuito Escolar S/N, Ciudad Universitaria, Coyoacán, Mexico City 04510, Mexico
- Unidad de Investigación en Farmacología, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosio Villegas, Secretaría de Salud, Calzada de Tlalpan 4502, Col. Belisario Domínguez Sección XVI, Tlalpan, Mexico City 14080, Mexico
- Instituto Politécnico Nacional (MX)
- Corresponding author
- Reyes-García, Juan Gerardo
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2021-12-12
- Volume
- 11
- Issue
- 12
- Pages
- 1354
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC8707701
- OpenAlex
- W4200311552
- Cited by
- 10
- References
- 31
- Citations by year
- 2026: 1 · 2024: 6 · 2022: 2
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Consejo Nacional de Ciencia y Tecnología (213481)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- phentermine, obesity, weight loss, drug tolerance, treatment efficacy prediction, anti-obesity drugs, interindividual variability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.